In November 2023, we opened a new clinical unit in Ostrava (CZ). We have now received all necessary certificates for operation (including European GCP), and client audits are currently underway.

In addition, preparations for the first studies are progressing well, and we estimate that very first study will be initiated by the second quarter of this year.

To remind you of the festive atmosphere of the ribbon-cutting ceremony, we have prepared a video of the opening speech below.

The speech was held by Stephan Holl, CEO of Conscio Group, Roman Grunt, CEO of Quinta – Analytica, Jiří Juchelka, PI of Quinta – Analytica, and in the name of cooperation by Cyril Kučera, Deputy for Medical Care of the Ostrava City Hospital.

Additional News

  • 25 listopadu 2024

    Expediting Biosimilar development: Streamlining the path from research to market

    On behalf of the Conscio Group, we would like to invite you to a free webinar on the future of the biosimilar pathway to approval, which is now open for registration.

  • 22 června 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency

  • 15 června 2023

    Novavax & Conscio: Behind the Scenes of Vaccine Development

    Discover how the Conscio Group and renowned vaccine manufacturer Novavax collaborate behind the scenes to ensure quality and efficiency in vaccine production.

ALL POSTS